Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Gilead Sciences | INDUSTRY |
| Taipei Institute of Pathology | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to clarify whether patients with chronic hepatitis B with high viral load will benefit from oral antiviral therapy despite only mildly elevated serum liver enzyme.
Chronic hepatitis B (CHB) is a serious disease in Taiwan, leading to substantial morbidity and mortality including hepatic failure, liver cirrhosis, and hepatocellular carcinoma (HCC). Recently a large body of evidence supports that high level of serum HBV DNA is an independent risk factor for late complications in CHB patients. Nucleos(t)ide analogues (NUC) are effective antiviral therapy that can potently inhibit replication of hepatitis B virus (HBV), and has been widely used in management of patients with CHB. Current practice guidelines recommend using serum alanine aminotransferase (ALT) > 2 times of the upper limit of normal (ULN) as the prerequisite to initiate antiviral therapy in compensated CHB patients without liver cirrhosis. However, serum ALT level does not exactly correlate with serum HBV DNA or liver tissue injury. Whether antiviral therapy improves outcomes of patients with slightly elevated ALT (i.e. 1-2 folds of ULN) remains unknown.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TDF | Experimental | tenofovir disoproxil fumarate (TDF) 300mg |
|
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| tenofovir disoproxil fumarate 300mg per day | Drug | tenofovir disoproxil fumarate 300mg per day for 3 years |
|
| Measure | Description | Time Frame |
|---|---|---|
| Severity of hepatic necroinflammation and fibrosis | Primary outcome is the severity of necroinflammation and fibrosis in liver tissue as evaluated by Knodell and Ishak scoring system | Within one month after completion of antiviral therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Undetectable hepatitis B viral DNA | HBV DNA viral DNA not detected in serum | Within one month after completion of antiviral therapy |
| Normalization of serum alanine aminotransferase | serum ALT <40 IU/mL |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yao-Chun Hsu, MD, MSc | E-Da Hospital, Kaohsiung, Taiwan | Principal Investigator |
| Jaw-Town Lin, MD, PhD | National Taiwan University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chia-Yi Christine Hospital | Chiayi City | 539 | Taiwan | |||
| E-Da Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33524314 | Derived | Hsu YC, Chen CY, Chang IW, Chang CY, Wu CY, Lee TY, Wu MS, Bair MJ, Chen JJ, Chen CC, Tseng CH, Tai CM, Huang YT, Ku WH, Mo LR, Lin JT. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect Dis. 2021 Jun;21(6):823-833. doi: 10.1016/S1473-3099(20)30692-7. Epub 2021 Jan 29. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019694 | Hepatitis B, Chronic |
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068698 | Tenofovir |
| ID | Term |
|---|---|
| D063065 | Organophosphonates |
| D009943 | Organophosphorus Compounds |
| D009930 | Organic Chemicals |
| D000225 | Adenine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo, identical to TDF in appearance, once daily for 3years |
|
| Within one month after completion of antiviral therapy |
| Serum level of HBsAg | quantification of serum HBV serface antigen | Within one month after completion of antiviral therapy |
| Serious adverse reaction | Defined as death, life threatening event, permanent or temporary disability, and hospitalization | Within one month after completion of antiviral therapy |
| Kaohsiung City |
| 824 |
| Taiwan |
| Taichung Veterans General Hospital | Taichung | 407 | Taiwan |
| Chi Mei Medical Center, Liouying | Tainan | Taiwan |
| Mackay Memorial Hosp | Taipei | 104 | Taiwan |
| National Taiwan University Hospital Yun-Lin Branch | Yunlin | 640 | Taiwan |
| D018347 |
| Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011687 |
| Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |